Nichi-Iko Pharmaceutical Co., Ltd.
http://www.nichiiko.co.jp/english
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nichi-Iko Pharmaceutical Co., Ltd.
Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments
Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.
Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
Lupin Liquidating Japan JV With Yoshindo, Partners I’Rom For Denosumab Biosimilar
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Large Molecule
- Other Names / Subsidiaries
-
- Elmed Eisai Co., Ltd
- Nichi-Iko Medical Practice Institution Co., Ltd.
- Yakuhan Pharmaceutical Co., Ltd.
- Nichi-Iko Pharma Tech Co., Ltd.
- Omega Laboratories Limited
- Sagent Pharmaceuticals Inc.
- Nihon Iyakuhin Kogyo Co., Ltd.